Additionally, evaluating the efficacy of small-molecule inhibitors targeting CREB5 or MYO10 in sepsis models may provide a theoretical basis for developing novel therapies targeting immune metabolism or cell cycle regulation. The gene discussed is CREB5; the disease is Sepsis.